Claims
- 1. A method of treating a T-helper cell type 2 -mediated immune disease or a disease mediated by T-helper cell type 2-related cytokines, which comprises administering to a subject having a T-helper cell type 2 -mediated immune disease or a disease mediated by T-helper cell type 2-related cytokines an effective amount of a compound selected from the group consisting of retinoid antagonists, pharmaceutically acceptable salts of retinoid antagonists,and pharmaceutically acceptable hydrolyzable esters of such retinoid antagonists and their salts.
- 2. The method of claim 1, wherein the T-helper cell type 2-mediated immune disease is an immunoglobulin E-mediated allergic disease.
- 3. The method of claim 2, wherein the immunoglobulin E-mediated allergic disease is atopic dermatitis.
- 4. The method of claim 2, wherein the immunoglobulin E-mediated allergic disease is allergic rhinitis.
- 5. The method of claim 2, wherein the immunoglobulin E-mediated allergic disease is allergic bronchial asthma.
- 6. The method of claim 1, wherein the disease mediated by Th2-related cytokines is mediated by IL-4 or IL-5.
- 7. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 8. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 9. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 10. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 11. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 12. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 13. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 14. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 15. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 16. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 17. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 18. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 19. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 20. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 21. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 22. The method of claim 1, wherein the compound is a retinoid antagonist of the formula:
- 23. The method of claim 1, wherein the administering comprises oral administration.
- 24. The method of claim 23, wherein the oral administration is at a daily dosage of from about 0.05 mg to about 20 mg of the compound per kg of body weight of the subject.
- 25. The method of claim 24, wherein the oral administration is at a daily dosage of from about 0.3 mg to about 1.5 mg of the compound per kg of body weight of the subject.
- 26. The method of claim 23, wherein the oral administration comprises administering a tablet, capsule, pill or sachet containing from about 5 mg to about 200 mg of the compound.
- 27. The method of claim 26, wherein the oral administration comprises administering a tablet, capsule, pill or sachet containing from about 20 mg to about 100 mg of the compound.
- 28. The method of claim 1, wherein the administering comprises topical administration.
- 29. The method of claim 28, wherein the topical administration comprises administering an ointment, cream, lotion, or spray containing from about 0.01 percent to about 5.0 percent by weight of the compound.
- 30. The method of claim 29, wherein the topical administration comprises administering an ointment, cream, lotion, or spray containing from about 0.1 percent to about 1.0 percent by weight of the compound.
- 31. The method of claim 1, wherein the administering comprises inhalation.
- 32. The method of claim 31, wherein the inhalation comprises administering a nasal aerosol, aerosol for inhalation, or dry powder for inhalation containing from about 0.01 percent to about 5.0 percent by weight of the compound.
- 33. The method of claim 32, wherein the inhalation comprises administering a nasal aerosol, aerosol for inhalations, or dry powder for inhalation containing from about 0.1 percent to about 1.0 percent by weight of the compound.
- 34. The method of claim 1, wherein the compound is a retinoid antagonists or a alkali metal salt, alkaline earth metal salt, benzyl ester, lower alkyl ester, or 9-fluorenylmethyl ester thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
97119776.9 |
Nov 1997 |
EP |
|
CROSS REFERENCE TO RELATED APPLICATION
[0001] This is a divisional of copending patent Application Ser. No. 09/189,189, filed Nov. 10, 1998.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09631655 |
Aug 2000 |
US |
Child |
10353523 |
Jan 2003 |
US |
Parent |
09189189 |
Nov 1998 |
US |
Child |
09631655 |
Aug 2000 |
US |